I76 Stock Overview
A healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ironwood Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.28 |
| 52 Week High | US$14.50 |
| 52 Week Low | US$3.16 |
| Beta | 0.47 |
| 11 Month Change | -12.77% |
| 3 Month Change | -21.90% |
| 1 Year Change | -61.86% |
| 33 Year Change | -67.04% |
| 5 Year Change | -70.18% |
| Change since IPO | -59.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| I76 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -14.1% | -0.7% | -0.02% |
| 1Y | -61.9% | -17.2% | 8.2% |
Return vs Industry: I76 underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: I76 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| I76 volatility | |
|---|---|
| I76 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: I76's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: I76's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 267 | Tom McCourt | www.ironwoodpharma.com |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.
Ironwood Pharmaceuticals, Inc. Fundamentals Summary
| I76 fundamental statistics | |
|---|---|
| Market cap | €513.28m |
| Earnings (TTM) | -€2.37m |
| Revenue (TTM) | €363.39m |
1.5x
P/S Ratio-223.5x
P/E RatioIs I76 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I76 income statement (TTM) | |
|---|---|
| Revenue | US$378.42m |
| Cost of Revenue | US$125.41m |
| Gross Profit | US$253.01m |
| Other Expenses | US$255.48m |
| Earnings | -US$2.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 66.86% |
| Net Profit Margin | -0.65% |
| Debt/Equity Ratio | -192.3% |
How did I76 perform over the long term?
See historical performance and comparison